CAS Medical Systems Company Profile (NASDAQ:CASM)

About CAS Medical Systems (NASDAQ:CASM)

CAS Medical Systems logoCAS Medical Systems, Inc. is a medical technology company that develops, manufactures and markets non-invasive patient monitoring products for patient care. The Company designs, manufactures and distributes the FORE-SIGHT and FORE-SIGHT ELITE brand tissue oximeters and sensors. It operates through Tissue Oximetry Monitoring, which includes sales of its FORE-SIGHT tissue oximeter monitors, sensors and accessories. The FORE-SIGHT Tissue Oximeter technology provides clinicians a non-invasive, quantitative measurement of oxygenation in cerebral tissue.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CASM
  • CUSIP: N/A
  • Web:
  • Market Cap: $21.86 million
  • Outstanding Shares: 27,329,000
Average Prices:
  • 50 Day Moving Avg: $0.88
  • 200 Day Moving Avg: $1.06
  • 52 Week Range: $0.74 - $1.94
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.71
  • P/E Growth: -0.19
Sales & Book Value:
  • Annual Revenue: $22.24 million
  • Price / Sales: 0.98
  • Book Value: ($0.49) per share
  • Price / Book: -1.63
  • EBITDA: ($4,050,000.00)
  • Net Margins: -32.59%
  • Return on Assets: -47.68%
  • Debt-to-Equity Ratio: -0.48%
  • Current Ratio: 1.86%
  • Quick Ratio: 1.62%
  • Average Volume: 42,488 shs.
  • Beta: -1.11
  • Short Ratio: 5.07

Frequently Asked Questions for CAS Medical Systems (NASDAQ:CASM)

What is CAS Medical Systems' stock symbol?

CAS Medical Systems trades on the NASDAQ under the ticker symbol "CASM."

How were CAS Medical Systems' earnings last quarter?

CAS Medical Systems, Inc. (NASDAQ:CASM) released its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.09) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.07) by $0.02. The company had revenue of $4.57 million for the quarter, compared to the consensus estimate of $5.41 million. View CAS Medical Systems' Earnings History.

When will CAS Medical Systems make its next earnings announcement?

CAS Medical Systems is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for CAS Medical Systems.

Who are some of CAS Medical Systems' key competitors?

Who are CAS Medical Systems' key executives?

CAS Medical Systems' management team includes the folowing people:

  • Thomas M. Patton, President, Chief Executive Officer, Director
  • Jeffrey A. Baird, Chief Financial Officer, Secretary
  • Kimberly K. Strusky, Executive Vice President - U.S. Sales
  • Paul B. Benni, Chief Scientific Officer
  • John K Gamelin Ph.D., Vice President - Research & Development
  • James E. Thomas, Lead Independent Director
  • Alan W. Milinazzo, Director
  • Paul A. Molloy, Director
  • Gregory P. Rainey, Independent Director
  • Kathleen A. Tune, Independent Director

How do I buy CAS Medical Systems stock?

Shares of CAS Medical Systems can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CAS Medical Systems' stock price today?

One share of CAS Medical Systems stock can currently be purchased for approximately $0.80.

MarketBeat Community Rating for CAS Medical Systems (NASDAQ CASM)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  41 (Vote Outperform)
Underperform Votes:  28 (Vote Underperform)
Total Votes:  69
MarketBeat's community ratings are surveys of what our community members think about CAS Medical Systems and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for CAS Medical Systems (NASDAQ:CASM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for CAS Medical Systems (NASDAQ:CASM)
Price Target History for CAS Medical Systems (NASDAQ:CASM)
Analysts' Ratings History for CAS Medical Systems (NASDAQ:CASM)
No equities research coverage for this company has been tracked by


Earnings History for CAS Medical Systems (NASDAQ:CASM)
Earnings by Quarter for CAS Medical Systems (NASDAQ:CASM)
Earnings History by Quarter for CAS Medical Systems (NASDAQ CASM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.06)N/AView Earnings Details
8/8/2017Q2 2017($0.07)($0.09)$5.41 million$4.57 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.06)($0.08)$5.73 million$5.23 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.03)($0.07)$5.49 million$5.48 millionViewListenView Earnings Details
11/8/2016Q3($0.05)($0.06)$5.85 million$5.76 millionViewListenView Earnings Details
8/4/2016Q2($0.05)($0.08)$5.58 million$5.50 millionViewN/AView Earnings Details
5/5/2016Q1($0.06)($0.03)$5.88 million$5.46 millionViewN/AView Earnings Details
3/9/2016Q4($0.07)($0.08)$5.20 million$5.80 millionViewListenView Earnings Details
11/5/2015Q315($0.09)($0.08)$5.66 million$5.50 millionViewN/AView Earnings Details
8/5/2015Q215($0.10)($0.09)$5.36 million$5.80 millionViewN/AView Earnings Details
5/5/2015Q115($0.10)($0.08)$5.21 million$5.80 millionViewN/AView Earnings Details
3/4/2015Q414($0.11)($0.11)$5.80 million$5.80 millionViewN/AView Earnings Details
11/4/2014Q3 2014($0.12)($0.10)$5.53 millionViewN/AView Earnings Details
8/6/2014Q214($0.11)($0.11)$5.00 million$5.80 millionViewN/AView Earnings Details
5/1/2014Q1 2014($0.13)($0.11)$5.71 millionViewN/AView Earnings Details
3/6/2014Q413($0.17)($0.19)$5.90 million$5.90 millionViewN/AView Earnings Details
11/12/2013Q3($0.19)$6.10 million$5.40 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.22)$5.20 million$5.00 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.14)ViewN/AView Earnings Details
11/8/2012Q312($0.14)$5.79 million$6.11 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for CAS Medical Systems (NASDAQ:CASM)
2017 EPS Consensus Estimate: ($0.31)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.07)($0.07)($0.07)
Q2 20171($0.06)($0.06)($0.06)
Q3 20171($0.09)($0.09)($0.09)
Q4 20171($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)


Dividend History for CAS Medical Systems (NASDAQ:CASM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for CAS Medical Systems (NASDAQ:CASM)
Insider Ownership Percentage: 36.00%
Institutional Ownership Percentage: 24.71%
Insider Trades by Quarter for CAS Medical Systems (NASDAQ:CASM)
Institutional Ownership by Quarter for CAS Medical Systems (NASDAQ:CASM)
Insider Trades by Quarter for CAS Medical Systems (NASDAQ:CASM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/26/2017James E FlynnInsiderSell636,238$1.46$928,907.48View SEC Filing  
1/23/2017James E FlynnInsiderSell205,126$1.53$313,842.78View SEC Filing  
5/15/2015Brian J WagnerInsiderBuy2,032$1.31$2,661.92View SEC Filing  
2/11/2015Thomas M PattonCEOBuy40,000$1.30$52,000.00View SEC Filing  
2/11/2015Thomas, Mcnerney & Partners IiMajor ShareholderBuy1,605,000$1.30$2,086,500.00View SEC Filing  
9/2/2014Thomas M PattonCEOBuy1,500$1.48$2,220.00View SEC Filing  
8/18/2014Thomas M PattonCEOBuy10,000$1.54$15,400.00View SEC Filing  
8/8/2014Thomas M PattonCEOBuy10,000$1.61$16,100.00View SEC Filing  
8/21/2013Thomas M PattonCEOBuy5,300$1.42$7,526.00View SEC Filing  
9/6/2012Thomas M PattonCEOBuy10,332$1.88$19,424.16View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for CAS Medical Systems (NASDAQ:CASM)
Latest Headlines for CAS Medical Systems (NASDAQ:CASM)
Loading headlines, please wait.



CAS Medical Systems (CASM) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.